Breaking News
FDA Grants RMAT Designation to 4D Molecular Therapeutics' 4D-150 for Diabetic Macular Edema

4D Molecular Therapeutics (4DMT) has announced that the U.S. Food and Drug Administration (FDA) has ...

read more
FDA Grants RMAT Designation to 4D Molecular Therapeutics' 4D-150 for Diabetic Macular Edema
May 05, 2025
FDA Grants Fast Track Designation to OKYO Pharma’s Urcosimod for Neuropathic Corneal Pain

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OKYO Pharma for it...

read more
FDA Grants Fast Track Designation to OKYO Pharma’s Urcosimod for Neuropathic Corneal Pain
May 05, 2025
FDA Expands Luminopia’s Label to Include Amblyopia Patients Aged 8 to 12

Luminopia has announced that the U.S. Food and Drug Administration (FDA) has expanded the label of i...

read more
FDA Expands Luminopia’s Label to Include Amblyopia Patients Aged 8 to 12
April 30, 2025
FDA Issues Complete Response Letter to Regeneron for EYLEA HD sBLA on Extended Dosing Intervals

Regeneron Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has issued ...

read more
FDA Issues Complete Response Letter to Regeneron for EYLEA HD sBLA on Extended Dosing Intervals
April 22, 2025
BVI Medical Receives FDA 510(k) Clearance for Leos Glaucoma Surgical System

BVI Medical has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its i...

read more
BVI Medical Receives FDA 510(k) Clearance for Leos Glaucoma Surgical System
April 18, 2025
FDA Accepts Outlook Therapeutics’ Biologics License Application for ONS-5010 in Wet AMD

The U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Applicati...

read more
FDA Accepts Outlook Therapeutics’ Biologics License Application for ONS-5010 in Wet AMD
April 10, 2025
FDA Approves Expanded Label for Iluvien to Include Chronic Noninfectious Uveitis

The FDA has approved an expanded label for Iluvien, allowing its use for the treatment of chronic no...

read more
FDA Approves Expanded Label for Iluvien to Include Chronic Noninfectious Uveitis
March 17, 2025
Atsena Therapeutics Receives FDA Fast Track Designation for ATSN-201 Gene Therapy in X-Linked Retinoschisis

Atsena Therapeutics has been granted Fast Track designation by the FDA for ATSN-201, its investigati...

read more
Atsena Therapeutics Receives FDA Fast Track Designation for ATSN-201 Gene Therapy in X-Linked Retinoschisis
March 13, 2025
Sydnexis Announces FDA Acceptance of NDA for SYD-101 in Pediatric Myopia Treatment

Sydnexis has reached a significant regulatory milestone with the FDA’s acceptance of its New Drug Ap...

read more
Sydnexis Announces FDA Acceptance of NDA for SYD-101 in Pediatric Myopia Treatment
March 12, 2025
FDA Approves Revakinagene Taroretcel-Lwey (ENCELTO) for Macular Telangiectasia Type 2

The US Food and Drug Administration (FDA) has granted approval for revakinagene taroretcel-lwey (ENC...

read more
FDA Approves Revakinagene Taroretcel-Lwey (ENCELTO) for Macular Telangiectasia Type 2
March 07, 2025
More